

# Anteo Diagnostics Limited

ABN 75 070 028 625

## SUPPLEMENTARY PROSPECTUS

**This document is important and should be read in its entirety together with the Prospectus. If you do not understand any part of this document, you should seek professional advice.**

### 1. Important Information

- 1.1 This is a Supplementary Prospectus intended to be read with the Prospectus dated 18 September 2009 (“**Prospectus**”) issued by Anteo Diagnostics Limited (“**Anteo**”) relating to a non-renounceable rights issue of Shares at 0.6 cents per share on the basis of 1 ordinary share for every 1 ordinary share held in Anteo, together with 1 Attaching Option (for no additional consideration) for every 1 Share subscribed for, at an exercise price of 1.2 cents.
- 1.2 This Supplementary Prospectus is dated 29 September 2009 and was lodged with the Australian Securities & Investments Commission (“**ASIC**”) on 29 September 2009. Neither ASIC nor ASX Limited take responsibility for the contents of this Supplementary Prospectus.
- 1.3 Pursuant to Section 719(4) of the Corporations Act, the Prospectus is taken to include this Supplementary Prospectus and must be read together with the Prospectus.
- 1.4 Terms defined in the Prospectus have the same meaning in this Supplementary Prospectus except where otherwise defined in this Supplementary Prospectus.

### 2. Sub-underwriting Arrangements

As disclosed at paragraph (a) at Section 8.2 of the Prospectus, one of the conditions of the Underwriting Agreement is the Underwriter entering into sub-underwriting firm commitment arrangements of at least 75% of the size of the Underwritten Amount. As at the date of this Supplementary Prospectus the Underwriter has received firm commitments representing 76.3% of the size of the Underwritten Amount. These commitments are subject to final sub-underwriting agreements.

If there are no applications for Shares under this Prospectus (such that there is a 100% Shortfall in the Offer), and after allowing for Shares to be taken up by sub-underwriters, the Underwriter's voting power in the Company would increase to approximately 18.63%. If only the Underwriter (in its capacity as a shareholder) takes up its full entitlement under the Offer, and after allowing for Shares to be taken up by sub-underwriters of the resultant Shortfall, the Underwriter's voting power in the Company would increase to approximately 23.80%.

### 3. Risk of Dilution to Shareholders

The issue price Shares under the Offer of 0.6 cents per Share represents a discount of approximately 45% to the Company's closing price prior to announcement of the Offer on ASX. Shareholders should be aware that, as the Offer is fully underwritten, if they do not apply for Shares up to their full pro-rata entitlement under the Offer, that their relative shareholding in the Company will be significantly diluted.

### 4. Underwriter's interests and Directors' Interest

At Sections 8.3 and 8.4 of the Prospectus it is disclosed that Mr James Henderson, a director of the Company, has a beneficial interest in the Underwriter and that the Underwriter is a company associated with him. The Underwriter is a related party of the Company as:

- (a) Mr Henderson is the ultimate beneficial owner of the Underwriter; and
- (b) Mr Henderson and Laura Iacusso, directors of the Company, are also directors of the Underwriter.

For personal use only

**5. Market Price of Shares**

5.1 Section 8.9 of the Prospectus is deleted and replaced with the following:

**8.9 Market Price of Shares**

The Company is a disclosing entity for the purposes of the Corporations Act and its Shares are enhanced disclosure securities quoted on ASX.

The highest, lowest and last market sale prices of the Shares on ASX during the three months immediately preceding the date of lodgment of the Prospectus with ASIC and the respective dates of those sales were:

Highest	1.7 cents	25 August 2009
Lowest	0.8 cents	24 August 2009
Last	1.1 cents	17 September 2009

This Supplementary Prospectus has been authorised and approved by a unanimous resolution of the directors of Anteo Diagnostics Limited.

---

**Geoffrey Cumming**  
**Director**

For personal use only